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Abstract: Transcription factor pancreatic and duodenal homeobox-1 (PDX-1) plays an 
essential role in pancreatic development, β-cell differentiation, maintenance of normal  
β-cell function and tumorigenesis. PDX-1 expression is tightly controlled through a variety 
of mechanisms under different cellular contexts. We report here that overexpression of 
Notch1 intracellular domain (NICD), an activated form of Notch1, enhanced PDX-1 
expression in both PDX-1 stable HEK293 cells and mouse insulinoma β-TC-6 cells, while 
NICD shRNA inhibited the enhancing effect. NICD-enhanced PDX-1 expression was 
accompanied by increased insulin expression/secretion and cell proliferation in β-TC-6 
cells, which was reversed by NICD shRNA. Cre activation-induced specific expression of 
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NICD in islet β cells of transgenic βNICD+/+ mice induced increased expression of PDX-1, 
insulin and proliferating cell nuclear antigen (PCNA) and decreased expression of p27 with 
accompanied fasting hyperinsulinemia and hypoglycemia and altered responses to 
intraperitoneal glucose tolerance test. Systemically delivered NICD shRNA suppressed 
islet expression of PDX-1 and reversed the hypoglycemia and hyperinsulinemia. 
Moreover, expression levels of NICD were correlated with those of PDX-1 in human 
pancreatic neuroendocrine tumor. Thus, Notch1 acts as a positive regulator for PDX-1 
expression, cooperates with PDX-1 in the development of insulin overexpression and islet 
cell neoplasia and represents a potential therapeutic target for islet neoplasia.  
Keywords: Notch1; NICD; PDX-1; insulin; hyperinsulinemia; hypoglycemia 
 
1. Introduction 
Pancreatic and duodenal homeobox-1 (PDX-1) is a homeodomain-containing transcription factor 
and plays an essential role in a variety of cellular processes, including pancreatic development, β-cell 
differentiation, maintenance of normal β-cell function and tumorigenesis. Targeted ablation of pdx-1 
gene in mice [1] and a homozygous nonsense mutation in the human pdx-1 gene [2] results in 
pancreatic agenesis. PDX-1 expression is essentially restricted to the islet β-cells in adults, where it 
binds to the promoters of several genes essential for glucose sensing and insulin synthesis, including 
insulin, glucose transporter 2, and glucokinase and regulates their expression. Mice with β-cell-specific 
ablation of pdx-1 develop overt diabetes [3], whereas heterozygosity for the null mutation of pdx-1 
results in decreased insulin expression/secretion [3,4] and predispose islets to apoptosis [5]. Gene 
mutations in human pdx-1 lead to the development of diabetes [6]. The involvement of PDX-1 in 
tumorigenesis is evidenced by its overexpression in a variety of human cancers including pancreatic 
neuroendocrine tumor (PNET) [7–13] and by the significant correlation of PDX-1 overexpression with 
the pathological parameters of cancer patients (e.g., metastasis and histological grade) [9,14]. Recent 
studies have demonstrated the oncogenic properties of PDX-1 as it stimulates cell proliferation, colony 
formation, invasion and tumor growth [15] and is required for K-RasG12D to induce the development of 
PanIN, metaplasia and pancreatic ductal adenocarcinoma [16]. Moreover, PDX-1 has been shown to 
be a potential therapeutic target for pancreatic cancer, insulinoma and islet neoplasia [11,17]. 
Notch proteins are a group of transmembrane receptors, including Notch1 to Notch 4 in mammals. 
Notch ligands include Delta-like 1, 3 and 4 and Jagged 1 and 2 in mammals. Notch signaling is 
initiated by cell-to-cell interaction-mediated binding of a Notch ligand to a Notch receptor. The 
interaction-induced proteolytic cleavages of Notch1 generates Notch1 intracellular domain (NICD) 
which subsequently translocates to the nucleus and regulates the expression of a wide array of target 
genes such as cell cycle-related regulators (e.g., p21 and Cyclin D1) [18,19], transcription factors (e.g., 
c-Myc and NF-κB) [20,21] and growth factor receptors (e.g., ErbB2) [22] dependent on the cellular 
contexts. The highly conserved Notch signaling plays an essential role in embryonic development, 
cellular differentiation, proliferation and survival [23–25] and tumorigenesis, as an oncogene or a 
tumor suppressor [26,27]. The Notch signaling has also been shown to be involved in the pathology of 
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diabetes. The pharmacological blockade of Notch signaling with inhibitors of γ-secretase, critical for 
the processing of the Notch proteins, raises insulin sensitivity [28]. Expression of an activated mutant 
of Notch (ICD-E) in both liver and small intestine in mice results in mild insulin resistance [29]. Mind 
bomb 1 is essential for generating functional Notch ligands to activate Notch and required for 
pancreatic β-cell formation [30,31]. A recent study shows that Notch signaling proteins HES-1 and 
Hey-1 bind to insulin degrading enzyme (IDE) proximal promoter and regulated its transcription and 
activity, suggesting a potential link between the Notch signaling and the expression/secretion of  
insulin [32].  
PDX-1 expression is subject to positive regulation by glucose [33], GLP-1 [34,35], palmitic acid [36] 
and EGF [37], and negative regulation by DNA damage stimulation [38], stress [39] and SSTR5 [40,41]. 
Cellular expression levels of PDX-1 are tightly controlled at both transcriptional [42–44] and  
post-translational levels [38,39,45–47]. A number of signaling pathways have been identified to be 
involved in regulation of PDX-1 expression, include AKT [37], PI3K [48], PKC [49], JNK [50] and 
p38 [51], positively or negatively, under different cellular contexts. The purpose of this study was to 
determine the role of Notch1 signaling in regulation of PDX-1 expression and PDX-1-mediated 
cellular functions. 
2. Results and Discussion 
2.1. Notch1 Intracellular Domain (NICD) Enhances PDX-1 Expression in PDX-1 Stable HEK 293 
Cells and β-TC-6 Cells 
To determine the role of Notch1 signaling in regulation of PDX-1 expression, we transfected 
Notch1 intracellular domain (NICD), activated form of Notch1, alone or NICD plus NICD shRNA 
(shRNANICD) into PDX-1 stable HEK293 cells [15]. Western blotting analysis showed that 
overexpression of NICD resulted in a significant increase of PDX-1 expression compared to that of 
mock transfection (Figure 1A, column 2 vs. column 1), while co-transfection of shRNANICD with 
NICD only resulted in a mild increase of PDX-1 expression (Figure 1A, column 3 vs. column 1). 
These data indicate that NICD, activated Notch1, acts as a positive regulator for PDX-1 expression and 
that NICD shRNA inhibits the enhancing effect of NICD on PDX-1 expression. To confirm the 
positive regulation of PDX-1 expression by Notch1 activation, we examined the effect of NICD 
shRNA (shRNANICD) on endogenous PDX-1 expression in mouse insulinoma β-TC-6 cells which have 
high expression level of PDX-1 [41]. shRNANICD was transfected into β-TC-6 cells. Western blotting 
analysis showed that NICD was abundant in β-TC-6 cells and transfection of shRNANICD resulted in a 
significant knockdown of endogenous NICD (Figure 1B, top panel). In parallel, PDX-1 expression 
level was also significantly decreased by transfection of shRNANICD in comparison to the mock 
transfection (Figure 1B, middle panel), further supporting the concept that activated Notch1 (NICD) is 
a positive regulator for PDX-1 expression. 
The underlying mechanism by which Notch1 activation up-regulates PDX-1 expression is not 
known. It has been well established that, upon ligand binding, NICD is released from the Notch 
protein and moves to the nucleus, where it regulates gene expression by interacting with and activating 
transcription factors such as CBF1/RBP-Jκ/Suppressor of Hairless/LAG-1 (CSL) transcription factor 
and p300 [52,53]. Given that PDX-1 is a potent transcription factor for PDX-1 itself, it is, thus, 
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possible that NICD may up-regulate the transcriptional activity of PDX-1, which, in turn, enhances the 
expression of PDX-1. However, we cannot exclude the possibility that NICD might enhance PDX-1 
expression by up-regulating other transcription factors, which target PDX-1. Further studies warrant  
a better understanding of the molecular basis for the positive regulation of PDX-1 expression by 
Notch1 activation. 
Figure 1. NICD up-regulates PDX-1 expression in PDX-1 stable HEK293 and β-TC-6 
cells. (A) pcDNAmNICD with shRNAmNICD_scrambled or shRNAmNICD were co-transfected into 
PDX-1 HEK293 cells using Lipofectamine 2000. (B) shRNAmNICD was transfected into  
β-TC-6 cells using Lipofectamine 2000. The cells were collected 40 hours after transfection. 
Whole cell lysates were subjected to SDS-PAGE, followed by Western blotting with an 
anti-NICD, -PDX-1 and β-actin antibody. Upper panels are representative Western blotting 
experiments. Lower panels are the densitometric analysis of three independent Western 
blotting experiments ( indicates p < 0.05 showing significant difference). 
 
2.2. Notch1 Activation-Enhanced PDX-1 Expression Is Accompanied by Increased Insulin 
Expression/Secretion and Cell Proliferation in β-TC-6 Cells 
PDX-1 plays an essential role in insulin expression and secretion [3,4] and cell proliferation [54]. 
To determine the functional relevance of the positive regulation of PDX-1 by NICD, we sought to 
examine the effect of NICD on PDX-1-mediated insulin expression/secretion and cell proliferation in 
β-TC-6 cells. β-TC-6 cells were transfected with NICD or shRNANICD. Immunohistochemistry analysis 
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showed that overexpression of NICD further increased NICD expression in β-TC-6 cells, while 
overexpression of shRNANICD inhibited NICD expression (Figure 2A, top panel). As expected, PDX-1 
expression level was increased by transfected NICD and decreased by transfected shRNANICD  
(Figure 2A, middle panel). Moreover, we found that NICD-enhanced PDX-1 expression was 
accompanied by increased insulin expression, and NICD knockdown-induced inhibition of PDX-1 
expression was accompanied by decreased insulin expression (Figure 2A, bottom panel). Insulin 
ELISA analysis showed that NICD overexpression significantly increased glucose stimulated insulin 
secretion (GSIS) in comparison to mock transfection, whereas shRNANICD led to significant inhibition 
of insulin secretion in β-TC-6 cells (Figure 2B). By performing MTS assays, we found that, at 24, 48 
and 72 hour after transfection, overexpression of NICD resulted in significant increases of β-TC-6 cell 
proliferation by 174 ± 18.2%, 185 ± 30.8% and 166 ± 21.3%, respectively, as compared to the mock 
transfection (Figure 2C). Conversely, transfection of shRNANICD led to significant decreases of cell 
proliferation by 63 ± 15.3%, 49 ± 8.8% and 56 ± 12.6% at each time point (Figure 2C). All these data 
indicate that Notch1 activation exerts a positive effect on insulin expression/secretion and cell 
proliferation likely through a mechanism of up-regulating PDX-1 expression in β-TC-6 cells. 
2.3. Notch1 Activation Induces Hypoglycemia and Hyperinsulinemia in a Transgenic βNICD+/+  
Mouse Model 
To further confirm the up-regulation of PDX-1 expression by Notch1 activation, we generated a 
transgenic βNICD+/+ mouse model by crossing LSL-ROSANICD mice [55] and RIP1-Cre mice, which 
resulted in β cell-specific expression of NICD within the islets. To determine the effect of NICD on 
PDX-1 and PDX-1-mediated cellular functions, the βNICD+/+ mice were treated at six months of age 
with or without liposomal shRNAmNICD at a dose of 35 μg per mouse via tail vein injection. The mice 
tolerated the treatment well with no toxic effects observed. Forty eight (48) hours after treatment of 
shRNAmNICD, the mice were sacrificed and the pancreata were isolated, fixed and prepared for 
immunohistochemistry analysis using anti-NICD, PDX-1, insulin, PNCA and p27 antibodies, 
respectively. As shown in Figure 3A, Cre activation induced a significant increase of NICD expression 
in islet cells of βNICD+/+ mice as compared to that of control mice, and systemically-delivered 
shRNAmNICD efficiently knocked down NICD (top panel). Cre activation-induced overexpression of 
NICD was accompanied by increased expression of PDX-1, insulin and proliferating cell nuclear 
antigen (PCNA) and a decreased expression of p27, an inhibitor of cyclin-dependent protein kinase, in 
islet cells of βNICD+/+ mice as compared to those of control mice. This is consistent with the finding that 
Notch directs the transcription of the E3 ubiquitin ligase S phase kinase-associated protein 2 (SKP2), 
which results in a decrease of p27 protein levels and an increase of cell proliferation [56]. In contrast, 
knockdown of NICD by systemically-delivered shRNAmNICD resulted in reduction of the expression of 
PDX-1, insulin and PCNA and increased expression of p27. These in vivo data further support the 
concept that Notch1 activation up-regulates insulin expression/secretion and cell proliferation through 
a mechanism involving enhancing PDX-1 expression. We noticed a previous study that PDX-1 
expression is not affected by NICD in both RosaN°tch/+;Pdx1-Cre and RosaN°tch;Pdx1-CreER  
mice [55]. The discrepancy may be due to the different Cre systems used (Pdx1-Cre and Pdx1-CreER 
vs. RIP1-Cre). In addition, the mice we analyzed were six months old, while the mice Murtaugh et al. 
analyzed were newborn or embryo [55]. 
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Figure 2. NICD-enhanced PDX-1 expression is accompanied by increased insulin 
expression/secretion and cell proliferation in β-TC-6 cells. mNICD or shRNAmNICD was 
transfected into β-TC-6 cells using Lipofectamine 2000. (A) Immunohistochemistry 
analyses were performed using antibodies against NICD, PDX-1 (1:200) or insulin (1:75). 
Fluorescence was developed using cy3- or FITC-conjugated secondary antibody. 
Photomicrographs were taken under 100× magnification. (B) Immunostaining for the 
expression of NICD, PDX-1 and insulin was semi-quantified using ImageJ ( indicates  
p < 0.05 showing significant difference). (C) Forty-eight (48) hours after transfection,  
β-TC-6 cells were washed twice with Krebs-Ringer bicarbonate (KRB) buffer and 
incubated in KRB-BSA for 1 hour. The cells were then added a variety of concentrations 
of glucose as indicated for 4 hours. After incubation, the media were collected and 
centrifuged at 600 g for 5 minutes. The insulin concentrations in the media were measured 
by ELISA assay ( indicates p < 0.05: Mock vs. mNICD transfection; p < 0.05: Mock vs. 
shRNAmNICD transfection, showing significant difference). (D) Twenty four (24) hours 
after transfection, β-TC-6 cells were replated into 96-well cell culture plates at  
5 × 103 cells/well. Cell proliferation was determined by MTS assay (Promega, Madison, 
WI, UAS) at 24, 48, and 72 hour after transfection. The absorbance was read using a 
Multiskan EX plate reader (Thermo Electronic Corp, Franklin, MA, USA) at 492 nm. 
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Figure 3. Overexpression of NICD-induced increase of PDX-1 expression is accompanied 
by the development of hypoglycemia and hyperinsulinemia in a βNICD+/+ transgenic mouse 
model. (A) Whole pancreatic tissues isolated from control mice (WT), βNICD+/+ mice and 
βNICD+/+ treated with shRNAmNICD were fixed in 4% (v/v) paraformaldehyde and embedded 
in paraffin. Immunohistochemistry analyses were performed using antibodies against 
NICD, PDX-1 (1:200), insulin (1:75), PCNA and p27. Fluorescence was developed using 
cy3- or FITC-conjugated secondary antibody. Photomicrographs were taken under 100× 
magnification. (B) Fifty (50) μL of whole blood samples were collected from control mice 
(WT), βNICD+/+ mice and βNICD+/+ mice treated with shRNAmNICD and spun to separate the 
serum. Glucose levels were measured using a Beckman-Coulter Glucose Analyzer 2 
(Coulter-Beckman, Fullerton, CA, USA), and presented as mean ± S.E.M. in mg/dl. Insulin 
levels were determined using a mouse insulin ELISA kit from Mercodia (Linco Research, 
St. Charles, MO, USA) and presented as mean ± S.E.M. in μg/L. (C) Control mice (WT) 
and βNICD+/+ mice at age of 6 months were fasted 6 hours before collection of blood 
samples as T0. Grouped mice were then given 1.2 g glucose/kg body weight via ip 
injection, followed by collection of blood samples at 15, 30, 60, 120 and 240 minute after 
injection of glucose. Glucose and insulin levels were measured as described above. 
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Given the essential role of PDX-1 in regulation of insulin expression/secretion, we hypothesized 
that NICD-induced increase of PDX-1 expression may lead to the development of hypoglycemia and 
hyperinsulinemia in βNICD+/+ mice. To test this hypothesis, glucose and insulin levels were measured in 
βNICD+/+ mice at six months of age. We found that glucose levels were significantly decreased and 
insulin levels were significantly increased in βNICD+/+ mice compared to those in control mice, while 
treatment of the βNICD+/+ mice with shRNAmNICD rescued/restored glucose and insulin levels close to 
wild type levels (Figure 3B). 
Next, we performed IPGTT in control (WT) and βNICD+/+ mice at six months of age to compare 
glucose tolerance. Basal insulin levels in βNICD+/+ mice were significantly higher than those in control 
mice (Figure 3C, top panel), whereas fasting glucose levels in βNICD+/+ mice were significantly lower 
than those in control mice (Figure 3C, bottom panel). Following intraperitoneal glucose injection, 
systemic insulin levels in βNICD+/+ mice were significantly higher than those in control mice at 15, 30, 
120 and 240 minute post-injection (Figure 3C, top panel). Glucose levels in βNICD+/+ mice were 
significant lower than those in control mice at 15, 30, 60, 240 minute post injection of glucose  
(Figure 3C, bottom panel). These data indicate that overexpression of NICD resulted in fasting 
hypoglycemia and hyperinsulinemia and alterations in insulin and glucose responses to IPGTT. 
Taken together, our studies show that NICD-enhanced PDX-1 expression was accompanied by 
increased insulin expression/secretion and cell proliferation in β cells of transgenic βNICD+/+ mice, 
resulting in hyperinsulinemia and hypoglycemia, as well as an altered response to IPGTT in these mice. 
A single systemic treatment with liposomal NICD shRNA resulted in in situ knockdown of NICD and 
PDX-1, leading to reversal of hyperinsulinemia and hypoglycemia. Moreover, there were no overt toxic 
side effects following the single treatment of liposomal NICD shRNA. This leads further support that 
Notch1 regulates PDX-1 expression and suggests that Notch1 could be a potential therapeutic target for 
hypoglycemic disorder using an RNAi platform. This is consistent with our recent studies showing  
that three-cycle treatment of PDX-1 shRNA reverses hyperinsulinemia and hypoglycemia in an  
immune-competent mouse model of islet neoplasia and results in significant reduction of tumor volume 
and improved survival in a human pancreatic cancer xenograft mouse model [11]. Our results also show 
that the transgenic βNICD+/+ mice with conditional induction of NICD in islet cells may serve as a 
potential novel mouse model for the development of islet cell neoplasia.  
2.4. Activation of Notch1 Is Associated with PDX-1 Overexpression in Human Pancreatic Neuroendocrine 
Tumors (PNETs) 
It has been reported that Notch1 is over-expressed in neuroendocrine tumors. We have recently shown 
that PDX-1 is markedly overexpressed in PNETs [41]. We, therefore, wanted to examine whether 
Notch1 activation is correlated with PDX1 overexpression in PNETs by performing IHC analysis of  
35 human PNET specimens. We found that Notch1 was activated in 31 of the 35 specimens (89%) as 
evidenced by NICD expression and that PDX-1 was expressed in all PNET specimens studied.  
Semi-quantitative analysis of the immunofluorescence images for NICD and PDX-1 using software 
ImageJ revealed that the median expression levels of PDX-1 were 85.2% and that of NICD was 63.8%. 
Moreover, we found that higher expression levels of NICD were accompanied by higher expression 
levels of PDX-1 (Figure 4A, right panel vs. left panel). Pearson correlations analysis showed significant 
correlation between PDX-1 and NICD expression (Figure 4B, R = 0.933; p < 0.01). These data further 
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support the concept that Notch1 activation up-regulates PDX-1 expression and that Notch1 activation 
may contribute to the overexpression of PDX-1 in PNETs. Notch1 has been reported to be expressed in 
PNET with accompanied expression of HES1, a downstream target of Notch1 [57]. Our studies showed 
that the majority of human PNET specimens expressed NICD in correlation with PDX-1 overexpression. 
Moreover, we found that NICD-enhanced PDX-1 expression was accompanied by increased cell 
proliferation in mouse insulinoma β-TC-6 cells and resulted in increased PCNA in the islets of transgenic 
βNICD+/+ mice. Given the oncogenic function of PDX-1 [15], our study suggests that Notch1 may play an 
oncogenic role in PNETs via up-regulating PDX-1. Cooperation with other oncogenes is one mechanism 
by which Notch1 exerts its oncogenic function. Our studies, thus, provide that up-regulation of PDX-1 is 
one novel mechanism by which Notch1 exerts its oncogenic functions. 
3. Experimental Section  
3.1. Cell Lines, Vectors, Antibodies and PNET Specimens  
Human embryonic kidney 293 (HEK 293) and mouse insulinoma β TC-6 cells were purchased from 
the American Type Culture Collection (ATCC, Bethesda, MD, USA) and maintained in Dulbecco’s 
modified Eagle medium (Gibco-BRL, Bethesda, MD, USA) supplemented with 100,000 U/L of 
penicillin, 100,000 µg/L of streptomycin, and 10% fetal bovine serum (FBS). pBS-Notch1-IC (mouse) 
was purchased from Addgene (plasmid 15079) and subcloned into pcDNA3.1 expressing vector to 
produce pcDNAmNICD. Human PDX-1 cDNA was polymerase chain reaction (PCR)-amplified from 
human islet cells and cloned into the FLAG epitope containing pCMV5 expression vector which was 
provided by Dr. Narasimhaswamy Belaguli (Baylor College of Medicine). Both mouse Notch1-IC and 
human PDX-1 were subcloned into retroviral vector pQICXIP (Clontech, Mountain View, CA, USA) 
for the purpose of retrovirus production. Five mouse Notch shRNAs targeting NICD (shRNAmNICD) 
were designed, synthesized and cloned into pSuper vectors. One of them targeting 
AGGCAACAGTGAAGAAGAA (starting 5661 of open reading frame of Notch1) was selected for the 
current study based on its most efficient knockdown effect. A scrambled shRNA was used as control. 
Goat anti-PDX-1 and rabbit anti-p27 and anti-PCNA antibodies were purchased from Santa Cruz 
Biotechnology Inc (Santa Cruz, CA, USA). Rabbit anti-activated Notch1 antibody that only recognizes 
the cleaved intracellular (activated) form of Notch1 (NICD) was purchased from Abcam (Cambridge, 
MA, USA). Monoclonal anti-insulin antibody was purchased from Sigma-Aldrich (St. Louis, MO, 
USA). Goat anti-rabbit antiserum and sheep anti-mouse antiserum conjugated with horseradish 
peroxidase were purchased from Amersham Life Science Inc. (Arlington Heights, IL, USA). Rabbit 
anti-goat IgG was obtained from Zymed Laboratories Inc. (South San Francisco, CA, USA). PNET 
specimens were as previously described [58]. 
3.2. Transient and Stable Transfection 
Transient transfection in HEK293 and β-TC-6 cells was performed with 24 µg of plasmid DNAs 
using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). Stable cell lines were established using 
retroviral expression system with pQCXIP retroviral vectors (Clontech, Mountain View, CA, USA). 
pQCXIP expressing PDX-1 was constructed and confirmed, followed by transfection into the 
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AmphoPack 293 cell line (Clontech, Mountain View, CA, USA) with Lipofactamine 2000 to produce 
retrovirus. The cells were infected with the supernatant containing the reconstructed retrovirus and 
selected with 10 mg/mL puromycin for two weeks. pcDNAmNICD with shRNAmNICD or shRNAmNICD_scrambled 
were co-transfected into β-TC-6 cells. 
Figure 4. Activation of Notch1 is associated with PDX-1 overexpression in human PNETs. 
Human PNET specimens were fixed in 4% (v/v) paraformaldehyde and embedded in 
paraffin. After deparaffinization in xylene and rehydration through graded alcohol, tissue 
sections were incubated with an anti-NICD (1:100) or an anti-PDX-1 antibody (1:200) 
overnight at 4 °C. Fluorescence was developed using FITC- or Cy3-conjugated secondary 
antibody. Simultaneous fluorescence microscopy observation and photography were 
carried out using an Olympus IX70 microscope (200×). (A) Shown are representative 
micrographs showing the expression levels of NICD and PDX-1 in PNET specimens.  
(B) Pearson correlations analysis showed significant correlation between PDX-1 and NICD 
expression in these specimens, R = 0.933; p < 0.01. 
 
3.3. Cell Proliferation Assays  
Twenty-four hours after transfection, cells were replated into 96-well cell culture plates at  
5 × 103 cells/well. Cell proliferation was determined by MTS assay (Promega, Madison, WI, USA) at 
24, 48, and 72 hour after transfection. The absorbance was read using a Multiskan EX plate reader 
(Thermo Electronic Corp, Franklin, MA, USA) at 492 nm. Levels of proliferation were determined 
according to the following formula: percentage of proliferation = 100 × B/A, where A is the 
absorbency at 492 nm of control cells, and B is the absorbency at 492 nm of treated cells.  
Genes 2013, 4 368 
3.4. Western Blotting  
Transfections were performed at 10-cm plates for 48 hours as described as previously. Cells were 
collected using a cell scrapper in an ice-cold phosphate-buffered saline (PBS) solution containing  
5 mM EDTA. Cells were lysed in a buffer containing 20 mM HEPES (pH 7.4), 2 mM EGTA, 50 mM 
β-glycerophosphatase, 1% Triton X-100, 10% glycerol, 1 mM DTT, 2 mg/mL of leupeptine, 5 mg/mL 
of aprotinin and 1 mM phenylmethylsulphonyl fluoride after two washes with PBS. Supernatants were 
collected after centrifugation at 100,000 g for 15 minutes at 4 °C. Twenty micrograms of cell lysates 
were analyzed using a sodium dodecyl sulfate-polyacrylamide gel electrophoresis gel (SDS-PAGE). 
After electrophoresis, gels were removed and blotted onto polyvinylidene fluoride (PVDF) 
membranes. Membranes were then incubated with 5% non-fat milk buffer and probed with antibodies 
against NICD and PDX-1. Immunocomplexes were visualized by enhanced chemiluminescence 
detection using horseradish peroxidase-conjugated secondary antibodies. Images were captured using 
the UVP imaging system, and the band was analyzed using ImageJ software. 
3.5. Generation of βNICD+/+ Mice 
LSL-RosaNICD transgenic mice were kindly provided by Dr. Brendan Lee (Baylor College of 
Medicine, Houston, TX, USA) with permission of use from Dr. Douglas Melton (Harvard University, 
Boston, MA, USA) [55]. The mice were maintained on a hybrid 129× C57BL/6 background. βNICD+/+ 
mice were generated by crossing LSL-RosaNICD and RIP1-Cre mice with successive generation 
screening. The βNICD+/+ mice at age of 6 months were treated with intravenous liposomal shRNAmNICD 
at dose of 35 μg per mouse via tail vein injection. Forty-eight (48) hours after injection, blood was 
collected and mice were sacrificed for tissues collection. Animals were used in accordance with the 
National Institutes of Health Guide for the Care and Use of Laboratory Animals. All mice were housed 
in a specific pathogen-free facility and under light-, temperature-, and humidity-controlled conditions. 
These studies were performed under IRB approval. 
3.6. Insulin and Glucose Measurements 
50 μL whole blood samples were collected and spun to separate the serum. Serum samples  
were stored at −20 °C until completion of experiments. Glucose levels were measured using a 
Beckman-Coulter Glucose Analyzer 2 (Coulter-Beckman, Fullerton, CA, USA), and presented as 
mean ± S.E.M. in mg/dL. Insulin levels were determined using a mouse insulin ELISA kit from 
Mercodia (Linco Research, St. Charles, MO, USA) and presented as mean ± S.E.M. in μg/L. 
3.7. Intraperitoneal Glucose Tolerance Test (IPGTT)  
Control (WT) and βNICD+/+ mice at age of six months were fasted 6 hours before collection of blood 
samples as T0. Grouped mice were then given 1.2 g glucose/kg body weight via ip injection, followed 
by collection of blood samples at 15, 30, 60, 120 and 240 minute after injection of glucose. Glucose 
and insulin levels were measured as described above. 
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3.8. Immunohistochemical Staining  
Fluorescein isothiocyanate-conjugated anti-rabbit IgG antibodies were purchased from Sigma (St. 
Louis, MO, USA). PNET tumors were fixed in 4% paraformaldehyde at 4 °C overnight. After 
treatment with 70% alcohol, tissue blocks were embedded in paraffin, and tissue sections were 
prepared. For immunostaining, sections were deparaffinized in xylene and hydrated gradually through 
graded alcohol. Slides were then placed in a humidified chamber, overlaid with diluted antibodies 
(1:100) against activated Notch1, PDX-1, insulin, PCNA or p27, and incubated overnight at 4 °C. 
After washing with PBS, slides were incubated with FITC-conjugated anti-rabbit or Cy3-conjugated 
anti-goat secondary antibody for 1 hour, then washed with PBS and mounted with cover slides. Images 
were recorded using a digital camera (Diagnostic Instruments Inc., Sterling Heights, MI, USA) on a 
fluorescent microscope (Olympus IX70; Olympus Optical Co Ltd., Japan). Immunostaining for PDX-1 
expression was semi-quantified using ImageJ. 
3.9. Statistical Analysis 
Student’s t-test was used to analyze difference in means of the continuous data. All numeric data 
are expressed as mean ± SEM, with p < 0.05 indicating significance. Pearson correlation analysis was 
used to analyze the correlation between PDX-1 and NICD expression 
4. Conclusions 
In this study, we provided biochemical and genetic evidence showing that Notch1 activation plays a 
positive role in regulation of PDX-1 expression as evidenced by the increased level of PDX-1 in  
PDX-1 stable HEK293 cells, β-TC-6 cells and in β cells of transgenic βNICD+/+ mice in the presence of 
NICD, a activated form of Notch1. We also found that NICD-enhanced PDX-1 expression was 
accompanied by increased insulin expression/secretion and cell proliferation in β-TC-6 cells and in 
islets of βNICD+/+ mice. βNICD+/+ mice were hyperinsulinemic and hypoglycemic, suggesting that Notch1 
activation results in islet neoplasia. Systemically-delivered NICD shRNA reversed the enhancing 
effect of NICD on PDX-1, as well as on hyperinsulinemia and hypoglycemia, suggesting that Notch1 
could be a potential therapeutic target. Thus, Notch1 may exert an oncogenic function in the 
development of islet cell neoplasia through cooperation with PDX-1. 
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